
HAS Early Access Program: Positive Trends After Two Years
The Haute Autorité de Santé (HAS) has recently shared a two-year summary of its Early Access program. The highlights include:

Pricing and Reimbursement in Germany – Possibility of price increases for legacy products
In an effort to control rising cost Germany introduced both a price freeze preventing price increases on legacy products effective